Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development
- 27 February 2018
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 104 (3) , 484-494
Abstract
Despite 50 years of extensive research, no definite drug is currently available to treat acute respiratory distress syndrome (ARDS), and the supportive therapies remain the mainstay of treatment. To improve drug development for ARDS, researchers need to deeply analyze the “omics” approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.Keywords
Funding Information
- National Natural Science Foundation of China (No. 81170016, No. 81170787, No. 81200022, No. 81200023, No. 81270067, No. 31571493, No. 81571928)
- Natural Science Foundation of Zhejiang Province (LY13H150002, LY12H16005)
This publication has 96 references indexed in Scilit:
- Unstressing intemperate models: how cold stress undermines mouse modelingJournal of Experimental Medicine, 2012
- Inflammasome-regulated Cytokines Are Critical Mediators of Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2012
- A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury*Critical Care Medicine, 2012
- A simple classification model for hospital mortality in patients with acute lung injury managed with lung protective ventilation*Critical Care Medicine, 2011
- Randomized, Placebo-controlled Clinical Trial of an Aerosolized β2-Agonist for Treatment of Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Gene Therapy for ALI/ARDSCritical Care Clinics, 2011
- ANGPT2 Genetic Variant Is Associated with Trauma-associated Acute Lung Injury and Altered Plasma Angiopoietin-2 Isoform RatioAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Functional Disability 5 Years after Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2011
- Resilience to Bacterial Infection: Difference between Species Could Be Due to Proteins in SerumThe Journal of Infectious Diseases, 2010
- Recent trends in acute lung injury mortality: 1996–2005*Critical Care Medicine, 2009